• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients
【24h】

Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients

机译：用于治疗2型糖尿病的蜜胶蛋白：日本和非日本患者的比较

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Canagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, improves various cardiometabolic parameters. Although canagliflozin was originally discovered in Japan, no comprehensive summary of its effects in Japanese patients has been reported. As differences exist in the pathologic features of diabetes between Japanese and non-Japanese populations, it is important to consolidate Japanese data for canagliflozin. Areas covered: The authors summarize Japanese clinical trial and post-marketing surveillance data for canagliflozin, and make comparisons with non-Japanese data. They also consider the therapeutic potential of canagliflozin in Japanese patients by presenting results from the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Expert opinion: In Japanese patients, canagliflozin 100 mg, administered as monotherapy or combination therapy, improved blood glucose, body weight, and blood pressure, and was well tolerated; the efficacy and safety profiles were comparable to previous clinical studies in other countries. In the CANVAS Program, canagliflozin reduced major cardiovascular events, and although Japan was not included in this program, canagliflozin may have cardiovascular benefits in Japanese patients, in whom control of multiple risk factors is important for preventing diabetic complications. Patients with high cardiovascular risk often have multiple comorbidities, so it is important to consider the risk–benefit balance of using SGLT2 inhibitors in individual patients.
机译：介绍：甲胶石，葡萄糖共转运蛋白-2（SGLT2）抑制剂，改善了各种心细镜型参数。虽然蜜霉兰最初在日本发现，但据报道，仍然没有综合其对日本患者的影响。随着日本和非日本群体之间糖尿病病理特征存在差异，巩固日本数据的蜜饯为蜜番。所涵盖的地区：作者总结了蜜番的日本临床试验和营销后的营销监测数据，并与非日本数据进行比较。他们还通过呈现蜜胶基噻唑辛血管性评估研究（CANVAS）计划的结果来考虑蜜胶蛋白在日本患者中的治疗潜力。专家意见：在日本患者中，蜜蜜醇100毫克，施用单药治疗或联合治疗，改善血糖，体重和血压，耐受良好;疗效和安全谱与其他国家的先前临床研究相媲美。在帆布计划中，蜜蜜杆菌素减少了主要的心血管事件，虽然日本未被列入这个程序，但蜜菌素可能对日本患者的心血管益处可能具有心血管益处，虽然对预防糖尿病并发症是重要的。患有高心血管风险的患者通常具有多种合并症，因此重要的是考虑使用SGLT2抑制剂在个体患者中的风险效益平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号